Global X Artificial Intelligence & Technology ETF vs Amgen, Inc. — how do they compare? Global X Artificial Intelligence & Technology ETF trades at $63.79, while Amgen, Inc. trades at $416.95 (market cap $224.14B). The key difference: Amgen, Inc. pays a 2.43% dividend while Global X Artificial Intelligence & Technology ETF pays none, and Amgen, Inc. is trading nearer its 52-week high, Global X Artificial Intelligence & Technology ETF nearer its low. Which is the better fit depends on your goals.
| AIQ | AMGN | |
|---|---|---|
Sector | Sector/Thematic | Health |
52-Week High | $70.14 | $417.20 |
52-Week Low | $43.88 | $271.18 |
Market Cap | — | $224.14B |
Enterprise Value | — | $267.45B |
Dividend Yield | — | 2.43% |
Signals from Pluang's Aura AI — not financial advice
AIQ, the Global X Artificial Intelligence & Technology ETF, trades at $63.79, up 0.44% on the day, with a bullish technical signal driven by moving averages. The ETF has gained attention for outperforming broader indices, with recent news highlighting its 25% gain and positioning in the AI sector. Key resistance lies at $64, while support is near $63.
The outlook remains positive due to strong momentum in AI investments, but risks include sector volatility and high valuations. Analyst sentiment is generally optimistic, with the ETF seen as a diversified play on AI growth, though the absence of dividend income and fee considerations may weigh on long-term returns.
AMGN trades at $417.44, up 0.06% on the day, with a bullish technical signal from moving averages but overbought RSI readings. The company reported strong Q2 2026 results, beating EPS estimates and raising full-year guidance, driven by robust product growth. Revenue reached $36.75B in 2025 with a net income margin of 22.95%, though high debt levels remain a focus.
Outlook is positive given earnings momentum and raised guidance, but risks include competitive pressures and a data breach investigation. Analyst consensus is Buy with a $394.69 price target, suggesting near-term consolidation after recent gains. The stock's valuation multiples are elevated relative to historical levels.
Trailing returns across standard periods
Latest headlines on both assets
AIQ invests in companies that benefit from the development and utilization of artificial intelligence. It focuses on hardware, software, and data giants at the center of the AI revolution, including NVIDIA, Meta, and Broadcom.
Read more on AIQ →Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →